Roche lowered its 2024 growth outlook in February as it continues to confront a drop-off in demand for its Covid-19 products and a number of its cancer drugs.
More Stories
We ranked the latest earnings reports from 30 portfolio stocks from great to ugly
Our companies' performances were reflective of the S&P 500 firms in aggregate.
Adobe stock slips on soft fourth-quarter revenue guidance
Adobe reported third-quarter results on Thursday that beat Wall Street expectations for sales and earnings.
Oracle bumps up fiscal 2026 revenue forecast, lifting stock 6%
Oracle is projecting higher revenue and capital expenditures as its cloud-computing arm grows.
These 5 portfolio stocks crushed the volatile market since our August Monthly Meeting
Investor concerns around the AI boom, coupled with the market's sensitivity to the Fed's next policy move, have caused Wall...
Goldman Sachs to post $400 million hit to third-quarter results as it unwinds consumer business
In late 2022, Goldman Sachs began to pivot away from its consumer operations, beginning a series of write-downs related to...
Oracle reports better-than-expected quarterly results; shares rise
While Oracle becomes more competitive in cloud infrastructure, it's also ensuring that competitors can offer its widely used database to...